{"xfid":"XF07BCVRH5","displayId":"XF-07BCVRH-5","status":"withdrawn","replacedBy":null,"statusReason":"reclassified_not_extra_financial","statusReasonLabel":"Not an extra-financial disclosure","statusNote":"This document is not an extra-financial disclosure (it is press coverage or other supporting material) and is therefore not listed in the registry.","statusAsOf":"2026-08-30","replacedByUrl":null,"record":{"title":"Amgen Response in Support of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias | Amgen","documentType":"PRESS","issuerName":"Amgen Inc.","issueYear":2019,"canonicalUrl":"https://www.amgen.com/newsroom/company-statements/amgen-response-in-support-of-the-2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias","retrievedAt":"2026-03-14T14:40:55.565601+00:00"}}